Other Events ·
Nasdaq Hearings Panel schedules November 10 hearing on NeuroSense delisting appeal
NRSNNeuroSense Therapeutics Ltd.
The Nasdaq Hearings Panel has scheduled a hearing for November 10, 2026, regarding NeuroSense Therapeutics' appeal of the October 1 staff determination to delist its securities. The company regained compliance with the $1.00 minimum bid price requirement but remains deficient in meeting the $35 million minimum market value of listed securities standard. Management intends to present a plan to satisfy listing requirements or an alternative equity standard during the hearing, requesting an exception period of up to 180 days. Shares continue trading pending the Panel's decision. The company also highlighted upcoming milestones, including a New Drug Submission for PrimeC in ALS targeted for December 2026 and a funding decision for its Phase 3 PARAGON trial expected in Q1 2027. NeuroSense Therapeutics is a late-stage clinical biotechnology company developing disease-modifying treatments for neurodegenerative diseases.